Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Imatinib mesylate is a prescription kinase inhibitor used for selected leukemias, myeloid disorders, gastrointestinal stromal tumors, and dermatofibrosarcoma protuberans. Current tablets include strengths equivalent to 100 mg and 400 mg of imatinib.
read more about imatinib ...Imatinib inhibits the BCR-ABL tyrosine kinase and also inhibits KIT and platelet-derived growth factor receptors. Blocking these abnormal or overactive kinase pathways reduces proliferation and promotes death of susceptible cancer cells.
Current labeling includes Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia, selected PDGFR-associated myelodysplastic or myeloproliferative disease, selected aggressive systemic mastocytosis, hypereosinophilic syndrome or chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and KIT-positive gastrointestinal stromal tumors.
Dosing depends on the disease. Adult chronic-phase CML uses 400 mg daily, while accelerated-phase or blast-crisis CML uses 600 mg daily. Adult relapsed or refractory Ph-positive ALL uses 600 mg daily, and unresectable or metastatic GIST uses 400 mg daily. Tablets are taken with a meal and a large glass of water.
Serious concerns include fluid retention, low blood-cell counts, heart failure, liver toxicity, bleeding, gastrointestinal complications, kidney toxicity, severe skin reactions, tumor lysis syndrome, and fetal harm. Complete blood counts and liver function are monitored during treatment.
Imatinib is a kinase inhibitor that targets BCR-ABL, KIT, and platelet-derived growth factor receptor signaling.
The recommended dose is 400 mg once daily.
Tablets are taken with a meal and a large glass of water.
Imatinib can cause anemia, neutropenia, and thrombocytopenia, so complete blood counts are monitored during therapy.
DailyMed - GLEEVEC - imatinib mesylate tablet. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b. Date Accessed October 2, 2026.
DailyMed - IMATINIB MESYLATE tablet, film coated. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07764bf9-21b4-4e32-9d7e-e348f8e4291f. Date Accessed October 2, 2026.
Imatinib - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a606018.html. Date Accessed October 2, 2026.
Imatinib Mesylate - National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate. Date Accessed October 2, 2026.
Search Orphan Drug Designations and Approvals - Imatinib. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=208905. Date Accessed October 2, 2026.